HOUSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 5,227,275 shares of its common stock ...

HOUSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 5,227,275 shares of its common stock at an offering price of $0.33 per share ...

Core Viewpoint - FibroBiologics has successfully repaid all outstanding convertible promissory notes, strengthening its balance sheet and eliminating further dilution from conversions [1][2][3] Financial Developments - The company has paid off the convertible promissory notes issued to Yorkville, which were part of a Standby Equity Purchase Agreement (SEPA) allowing the sale of up to $25 million in common stock [1][2] - The first $15 million was advanced in three equal tranches, and with the repayment, there will be no further conversions into shares [2] - The SEPA remains active until December 20, 2026, permitting the company to sell an additional $10 million of its common stock under certain conditions [2] Strategic Focus - The repayment of convertible debt allows the company to concentrate on advancing its clinical programs, particularly the initiation of first-in-human trials [3] - The company is preparing to start a Phase 1/2 clinical trial for its fibroblast-based product candidate CYWC628 in diabetic foot ulcer patients in early 2026 [4] - Additionally, the company plans to submit Investigational New Drug applications for treatments targeting psoriasis and multiple sclerosis [4] Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing therapeutics for chronic diseases using fibroblast cells [8] - The company holds over 270 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, and cancer [8]

Core Viewpoint - FibroBiologics, Inc. has successfully closed a registered direct offering of 4,477,614 shares of common stock at $0.335 per share, raising approximately $1.5 million, with additional potential proceeds from unregistered warrants [1][3] Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 270 patents [1][9] - The company is engaged in various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [9] Offering Details - The registered direct offering was priced at-the-market under Nasdaq rules, and the unregistered warrants were issued concurrently, allowing for the purchase of an equal number of shares at the same exercise price [1][3] - The gross proceeds from the offering were approximately $1.5 million before fees and expenses, with the potential for an additional $1.5 million if the unregistered warrants are fully exercised [3] Regulatory Compliance - The shares offered in the registered direct offering were made under a "shelf" registration statement filed with the SEC, and a final prospectus supplement was filed with the SEC [4] - The unregistered warrants were offered in a private placement and have not been registered under the Securities Act, limiting their sale in the U.S. [5]

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials [1][3] - The company holds over 270 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [3] Company Presentation - The CEO, Pete O'Heeron, will present at the 2025 ThinkEquity Conference on October 30 at 4:30 p.m. ET [2] - FibroBiologics will also be available for one-on-one investor meetings during the event [2] Company Overview - FibroBiologics is based in Houston and represents the next generation of medical advancement in cell therapy and tissue regeneration [3] - The company is actively developing a pipeline of treatments aimed at chronic diseases [3]

Core Viewpoint - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, with over 275 patents issued and pending [1][3]. Company Presentation - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 12:00 p.m. ET and will be available for one-on-one investor meetings throughout the event [2]. Company Overview - FibroBiologics is based in Houston and is developing a pipeline of treatments targeting chronic diseases, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [3]. - The company represents a new generation of medical advancements in cell therapy and tissue regeneration [3].

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology, holding over 275 patents [1][6] - The company will present its recent research on fibroblast-based technology for wound healing and psoriasis at the Advanced Wound Care Summit on July 15, 2025 [1][2] Company Overview - FibroBiologics is based in Houston and is developing a pipeline of treatments aimed at chronic diseases, including diabetic foot ulcers, multiple sclerosis, and cancer [6] - The company emphasizes a novel approach to treatment that leverages the body's natural regenerative processes rather than merely managing symptoms [2][6] Upcoming Events - The Advanced Wound Care Summit will take place from July 15 to 17, 2025, in Boston, featuring global leaders in wound care innovation and clinical research [3] - The presentation by CEO Pete O'Heeron is scheduled for July 15, 2025, at 2 p.m. ET at the Marriott Courtyard Boston Downtown [3]

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology [1][4] - The company will present updates on its recent milestones and research at the BIO International Convention 2025, highlighting advancements in wound healing, multiple sclerosis, and psoriasis [1][2] Company Overview - FibroBiologics holds over 275 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [4] - The company aims to transform the treatment landscape for chronic diseases by addressing underlying biological dysfunction rather than merely managing symptoms [2][4] Upcoming Events - The presentation at the BIO International Convention is scheduled for June 17, 2025, at 10:45 a.m. ET, at the Boston Convention & Exhibition Center [2] - The company is set to begin a Phase 1/2 clinical trial for diabetic foot ulcers later this year, marking a significant step in its research efforts [2]

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblast cells and materials [1][3] - The company holds over 240 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [3] - Hamid Khoja, Ph.D., the Chief Scientific Officer, will present at The Cell & Gene Meeting On The Mediterranean in Rome, highlighting a fibroblast cell-based therapeutic approach targeting chronic inflammation-mediated diseases [1][2] Company Overview - FibroBiologics is based in Houston and represents a new generation of medical advancements in cell therapy and tissue regeneration [3] - The company is actively engaged in the development of a pipeline of treatments aimed at chronic diseases, leveraging its extensive patent portfolio [3] Conference Details - The presentation titled "Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases" will take place on April 16, 2025, at 9:00 AM CEST [2] - The event is a significant gathering for the Advanced Therapy Medicinal Products community from Europe and beyond [1][2]

Core Insights - FibroBiologics, Inc. has opened a new laboratory facility to enhance its research capabilities for chronic disease therapeutics using fibroblast technology [1][2][3] - The new facility spans over 10,000 square feet and will support in-house GMP manufacturing for drug product candidates [2][3] - The expansion aims to accelerate innovation, increase research efficiency, and reduce reliance on external partners [3] Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing treatments and potential cures for chronic diseases through fibroblast cells and materials [6] - The company holds over 240 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, and cancer [6] Future Plans - The company plans to hire additional researchers to support the new laboratory and its mission to combat chronic diseases [2][3] - The expansion is expected to facilitate the exploration of a broader pipeline of therapeutic candidates and enhance collaboration among research teams [3]